FDA approves Activ-Blister packaging solution for oral solid dose HIV prevention medicine

The system protects oral solid drug products with a 3-Phase Activ-Polymer solution that is fully integrated into the blister package.

AptarGroup has announced that its Activ-Blister packaging solution for oral solid dose drug delivery has been approved by the FDA for an HIV prevention medicine.

Aptar’s Activ-Blister packaging solution.

The oral solid dose drug was developed by a leading pharmaceutical company in the HIV treatment and prevention space, and represents the first FDA approval of Aptar’s proprietary Activ-Blister packaging solution and proprietary application process developed by Aptar CSP Technologies.

The system protects oral solid drug products with a 3-Phase Activ-Polymer solution that is fully integrated into the blister package. This 3-Phase Activ-Polymer technology, which can be customized specifically for the drug developer’s formulation, offers a broad spectrum of specific drug protection including moisture adsorption, and oxygen and odor scavenging. The technology can also scavenge volatile organic compounds (VOCs) and emit aromas.

Aptar’s portfolio of 3-Phase Activ-Polymer protective solutions helps biotech and pharmaceutical partners meet specific drug long-term and in-use stability requirements while maintaining therapeutic efficacy, all in a patient-friendly packaging configuration.

“I am very pleased to announce this recent FDA approval of our proprietary Activ-Blister technology,” commented Stephan Tanda, Aptar’s President and CEO. “This is a significant step that further validates the expanding portfolio of solutions offered by Aptar CSP Technologies. We will continue to leverage our proprietary 3-Phase Activ-Polymer technology to help our customers with unique protective formulations that derisk their drug development process and help strengthen their own offerings. The ultimate result is that we are creating meaningful solutions that help improve and save lives.”